Bio-Path Holdings, Inc.2024财年第二财季实现净利润-1.87百万美元，同比增加55.79%

市场透视08-23

8月23日，Bio-Path Holdings, Inc.（BPTH.US）公布财报，公告显示公司2024财年第二财季净利润为-1.87百万美元，同比增加55.79%；其中营业收入为0.00美元，每股基本收益为-1.16美元。从资产负债表来看，Bio-Path Holdings, Inc.（BPTH.US）总负债3.83百万美元，其中短期债务55000.00美元，资产负债比为1.34，流动比率为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461347666?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2461347666","market":"us","top_or_hot":-1,"title":"Bio-Path Holdings, Inc.2024财年第二财季实现净利润-1.87百万美元，同比增加55.79%","media":"市场透视","content":"<div>\n<p>8月23日，Bio-Path Holdings, Inc.（BPTH.US）公布财报，公告显示公司2024财年第二财季净利润为-1.87百万美元，同比增加55.79%；其中营业收入为0.00美元，每股基本收益为-1.16美元。从资产负债表来看，Bio-Path Holdings, Inc.（BPTH.US）总负债3.83百万美元，其中短期债务55000.00美元，资产负债比为1.34，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408230000289f4898b7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Path Holdings, Inc.2024财年第二财季实现净利润-1.87百万美元，同比增加55.79%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Path Holdings, Inc.2024财年第二财季实现净利润-1.87百万美元，同比增加55.79%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408230000289f4898b7&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月23日，Bio-Path Holdings, Inc.（BPTH.US）公布财报，公告显示公司2024财年第二财季净利润为-1.87百万美元，同比增加55.79%；其中营业收入为0.00美元，每股基本收益为-1.16美元。从资产负债表来看，Bio-Path Holdings, Inc.（BPTH.US）总负债3.83百万美元，其中短期债务55000.00美元，资产负债比为1.34，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408230000289f4898b7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BPTH","symbol_name":"Bio-Path Holdings, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408230000289f4898b7&s=b","article_id":"2461347666","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408230000289f4898b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2461347666","pubTimestamp":1724342424,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月23日，Bio-Path Holdings, Inc.公布财报，公告显示公司2024财年第二财季净利润为-1.87百万美元，同比增加55.79%；其中营业收入为0.00美元，每股基本收益为-1.16美元。从资产负债表来看，Bio-Path Holdings, Inc.总负债3.83百万美元，其中短期债务55000.00美元，资产负债比为1.34，流动比率为1.67。机构评级：截至2024年8月23日，当前有1家机构对Bio-Path Holdings, Inc.目标价做出预测，其中目标均价为20.00美元，其中最低目标价为20.00美元，最高目标价为20.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"BPTH":"Bio-Path Holdings, Inc."},"translate_title":"Bio-Path Holdings, Inc. achieved net profit of-1.87 million US dollars in the second fiscal quarter of fiscal year 2024, a year-on-year increase of 55.79%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPTH":1},"content_text":"8月23日，Bio-Path Holdings, Inc.（BPTH.US）公布财报，公告显示公司2024财年第二财季净利润为-1.87百万美元，同比增加55.79%；其中营业收入为0.00美元，每股基本收益为-1.16美元。从资产负债表来看，Bio-Path Holdings, Inc.（BPTH.US）总负债3.83百万美元，其中短期债务55000.00美元，资产负债比为1.34，流动比率为1.67。机构评级：截至2024年8月23日，当前有1家机构对Bio-Path Holdings, Inc.目标价做出预测，其中目标均价为20.00美元，其中最低目标价为20.00美元，最高目标价为20.00美元。公司简介：Bio-Path Holdings Inc 是一家专注于临床和临床前阶段肿瘤学的 RNAi 纳米颗粒药物开发公司。 它致力于利用一项新技术，用以实现对疾病中过度表达的任何基因产物的靶标特异性蛋白质抑制的系统递送。 该公司的候选药物 prexigebersen 正处于与低剂量阿糖胞苷（LDAC）联合治疗以及与地西他滨联合治疗急性髓性白血病（AML）的 2 期临床试验的疗效部分。 该公司的其他药物有BP1002、BP1003、BP1001-A和DNABILIZE。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461347666"}